@shilpaonc @ClevelandClinic w #MAINCAV results — Cabo-avelumab vs avelumab in maintenance #bladdercancer. Closed after 10% pts accrued 2/2 EV-pembro landscape changes. Valiant effort from @ALLIANCE_org.
#ASCO26 @asco @oncoalert @urotoday